In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
News|Articles|September 19, 2024
New Pembrolizumab Data Presented at ESMO Show Promise in a Variety of Cancers
Pembrolizumab is an anti-programmed death receptor 1 (PD-1) therapy designed to increase the immune system’s ability to detect and fight tumor cells.
Advertisement
Advertisement
Multiple new trial results have been presented at the European Society for Medical Oncology (ESMO) Congress 2024 supporting the use of pembrolizumab (Keytruda; Merck) in a variety of cancer types, including breast cancer, melanoma, hepatocellular carcinoma, and cervical cancer.
Related to this article
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
Tucatinib’s new HER2-positive breast cancer maintenance indication extends disease control while requiring close liver monitoring and pharmacist coordination of oral therapy with ongoing antibody treatment.
Danielle Roman, PharmD, BCOP, FHOPA, explains how ASCO’s updated breast cancer surveillance guideline links follow-up intensity to recurrence risk and creates opportunities for pharmacist involvement.
After initial breast cancer treatment, pharmacists can help patients navigate ongoing endocrine therapy, manage persistent adverse effects, and address medication concerns that affect long-term care.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Advertisement
Advertisement